Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Itraconazole and Rifampicin on Molibresib PK
NCT02706535Phase 1Completed
- Sponsor
- GSK
- Start
- May 2016
- Primary completion
- Jan 2017
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of molibresib in neoplasms (3 arms), sponsored by GSK. Primary endpoints: Area under the plasma concentration-time curve from pre dose to time 't' at Day 18, Area under the plasma concentration-time curve from pre dose to infinite time at Day 18 and 2 more. Started May 2016; status: completed.
02
Drugs
molibresib
03
Conditions
neoplasms
Beyond the preview
Go deeper on NCT02706535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02706535.